Open Journal Systems

The Effect of Thymoquinone on BEAS-2B Cell Viability and TGF-β1 Release

Hasret Ecevit ()
Kubra Gunduz ()
Nilufer Bilgic ()
Muzeyyen Izmirli ()
Bulent Gogebakan ()


Thymoquinone, one of the essential oil in the structure of cumin, is used for alternative therapy for many diseases from past to present. It was shown to have anti-carcinogenic and anti-inflammatory effects, as well as positive effects on fibrosis. However, there is no study on the effect of thymoquinone on cancer and fibrosis mechanism in bronchial epithelium cell line BEAS-2B. In our study, the effect of thymoquinone on cell viability and transforming growth factor-beta 1 (TGF-β1) level, which has an important role in the regulation of many biological processes including cancer and fibrosis-associated signal transduction, was evaluated. BEAS-2B cells were exposed to thymoquinone at 0–80 μmol/L concentrations for 24-, 48- and 72-hour durations. Cell viability was evaluated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test. TGF-β1 level was determined with enzyme-linked immunosorbent assay (ELISA) method from the collected supernatant. Cell viability was found to be increased at all concentrations and durations (10–80 μmol/L; 24, 48 and 72 h) according to the control group (0 μmol/L; thymoquinone in ethanol) (p < 0.0001). Moreover, thymoquinone was found to increase the level of TGF-β1 only at 80 μmol/L concentration and 24-hour exposure period (0 μmol/L, 53.41 ± 18.44 pgr/ml TGF-β1; 80 μmol/L, 174.5 ± 80.03 pgr/ml TGF-β1). As a result, thymoquinone was found to increase cell proliferation and encourage TGF-β1 release.


BEAS-2B; thymoquinone; fibrosis; cancer; TGF-β1.

Full Text:



Güllü EB, Gulcan A. Timokinon: Nigella sativa’nın biyoaktif komponenti (Turkish) [Thymoquinone: The bioactive component of Nigella sativa]. Kocatepe Vet J 2013; 6(1).

Pari L, Sankaranarayanan C. Beneficial effects of thymoquinone on hepatic key enzymes in streptozotocinnicotinamide induced diabetic rats. Life Sci 2009; 85(23–26): 830–834. doi: 10.1016/j.lfs.2009.10.021.

Kaseb AO, Chinnakannu K, Chen D, Sivanandam A, Tejwani S, et al. Androgen receptor- and E2F-1-targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res 2007; 67(16): 7782–7788. doi: 10.1158/0008-5472.CAN-07-1483.

Badary OA. Thymoquinone attenuates ifosfamide-induced Fanconi syndrome in rats and enhances its antitumor activity in mice. J Ethnopharmacol 1999; 67(2): 135–142. doi: 10.1016/S0378-8741(98)00242-6.

Kanter M, Coskun O, Budancamanak M. Hepatoprotective effects of Nigella sativa L and Urtica dioica L on lipid peroxidation, antioxidant enzyme systems and liver enzymes in carbon tetrachloride-treated rats. World J Gastroenterol 2005; 11(42): 6684–6688. doi: 10.3748/wjg.v11.i42.6684.

Badary OA, Abdel-Naim AB, Abdel-Wahab MH, Hamada FM. The influence of thymoquinone on doxorubicin-induced hyperlipidemic nephropathy in rats. Toxicology 2000; 143(3): 219–226. doi: 10.1016/S0300-483X(99)00179-1.

Al-Shabanah OA, Badary OA, Nagi MN, Al-Gharably NM, Al-Rikabi AC, et al. Thymoquinone protects against doxorubicin-induced cardiotoxicity without compromising its antitumor activity. J Exp Clin Cancer Res 1998; 17(2): 193–198.

Salem ML. Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. Int Immunopharmacol 2005; 5(13–14): 1749–1770. doi: 10.1016/j.intimp.2005.06.008.

Darakhshan S, Pour AB, Colagar AH, Sisakhtnezhad S. Thymoquinone and its therapeutic potentials. Pharmacol Res 2015; 95–96: 138–158. doi: 10.1016/j.phrs.2015.03.011.

Woo CC, Kumar AP, Sethi G, Tan KH. Thymoquinone: Potential cure for inflammatory disorders and cancer.

Biochem Pharmacol 2012; 83(4): 443–451. doi: 10.1016/j.bcp.2011.09.029.

Krstić J, Trivanović D, Mojsilović S, Santibanez JF. Transforming growth factor-beta and oxidative stress

interplay: Implications in tumorigenesis and cancer progression. Oxid Med Cell Longev 2015; 2015: 654594. doi: 10.1155/2015/654594.

Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A 2003; 100(15): 8621–8623. doi: 10.1073/pnas.1633291100.

Hughes R, Ward D, Tobin AM, Keegan K, Kirby B. The use of alternative medicine in pediatric patients with atopic dermatitis. Pediatr Dermatol 2007; 24(2): 118–120. doi: 10.1111/j.1525-1470.2007.00355.x.

Chen YF, Chang JS. Complementary and alternative medicine use among patients attending a hospital dermatology clinic in Taiwan. Int J Dermatol 2003; 42(8): 616–621. doi: 10.1046/j.1365-4362.2003.01809.x.

Clarke TC, Black LI, Stussman BJ, Barnes PM, Nahin RL. Trends in the use of complementary health approaches among adults: United States, 2002–2012. Natl Health Stat Report 2015; (79): 1–16.

Loganathan RS, Stover DE, Shi W, Venkatraman E. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest 2006; 129(5): 1305–1312. doi: 10.1378/chest.129.5.1305.

Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J 2009; 34(2): 380–386. doi: 10.1183/09031936.00144208.

Park J, Kim DS, Shim TS, Lim CM, Koh Y, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J 2001; 17(6): 1216–1219. doi: 10.1183/09031936.01.99055301.

Kanter M. Thymoquinone attenuates lung injury induced by chronic toluene exposure in rats. Toxicol Ind Health 2011; 27(5): 387–395. doi: 10.1177/0748233710387630.

El-Khouly D, El-Bakly WM, Awad AS, El-Mesallamy HO, El-Demerdash E. Thymoquinone blocks lung injury and fibrosis by attenuating bleomycin-induced oxidative stress and activation of nuclear factor Kappa-B in rats. Toxicology 2012; 302(2–3): 106–113. doi: 10.1016/j.tox.2012.09.001.

Ghazwani M, Zhang Y, Gao X, Fan J, Li J, et al. Antifibrotic effect of thymoquinone on hepatic stellate cells.

Phytomedicine 2014; 21(3): 254–260. doi: 10.1016/j.phymed.2013.09.014.

Bai T, Lian LH, Wu YL, Wan Y, Nan JX. Thymoquinone attenuates liver fibrosis via PI3K and TLR4 signaling pathways in activated hepatic stellate cells. Int Immunopharmacol 2013; 15(2): 275–281. doi: 10.1016/j.intimp.2012.12.020.

Kong LY, Li GP, Yang P, Xi Z. Protective effect of thymoquinone on cholestatic rats with liver injury. Genet Mol Res 2015; 14(4): 12247–12253. doi: 10.4238/2015.October.9.13.

Bai T, Yang Y, Wu YL, Jiang S, Lee JJ, et al. Thymoquinone alleviates thioacetamide-induced hepatic fibrosis and

inflammation by activating LKB1-AMPK signaling pathway in mice. Int Immunopharmacol 2014; 19(2): 351–357. doi:10.1016/j.intimp.2014.02.006.



  • There are currently no refbacks.

Copyright (c) 2018 Hasret Ecevit, Kubra Gunduz, Nilufer Bilgic, Muzeyyen Izmirli, Bulent Gogebakan

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.